目的 探討倍他司汀聯(lián)合尼麥角林治療腦梗死恢復期的臨床療效。方法 回顧性選取2022年6月—2024年6月蕪湖市第五人民醫(yī)院收治的腦梗死恢復期患者80例，按照隨機數(shù)字法分為對照組和治療組，每組40例。對照組口服尼麥角林膠囊，1粒/次，1次/d。在對照組基礎(chǔ)上，治療組口服鹽酸倍他司汀片，2片/次，3次/d。兩組治療15 d。觀察兩組患者臨床療效，比較治療前后兩組患者Fugl-Meyer運動量表（FMA）和日常生活活動能力表（BI）評分及同型半胱氨酸（HCY）、神經(jīng)生長因子（NGF）、白細胞介素-18(IL-18)和神經(jīng)營養(yǎng)因子（NTF）水平。結(jié)果 治療后，治療組總有效率97.50%高于對照組的77.50%(P<0.05)。治療后，兩組患者FMA評分和BI評分比治療前升高（P<0.05），且治療后治療組評分均高于對照組（P<0.05）。治療后，兩組患者HCY、IL-18水平比治療前降低，而NGF、NTF水平升高（P<0.05），且治療后，治療組HCY、IL-18、NGF和NTF水平優(yōu)于對照組（P<0.05）。結(jié)論 尼麥角林聯(lián)合倍他司汀治療腦梗死恢復期，能有效緩解患者癥狀，患者日常生活能力提升較高。

Objective To explore the clinical efficacy of betahistine combined with nicergoline in treatment of cerebral infarction in the recovery period. Methods A total of 80 patients in the convalescent stage of cerebral infarction admitted to the Fifth People’s Hospital of Wuhu from June 2022 to June 2024 were retrospectively selected and divided into control group（40 cases） and treatment group（40 cases） according to random number method. The control group took Nicergoline Capsules orally, 1 capsule/time, once a day.On the basis of the control group, the treatment group was given Betahistine Hydrochloride Tablets, 2 tablets/times, 3 times a day. Both groups were treated for 15 d. After treatment, the clinical evaluations were evaluated, the scores of FMA and BI, and the levels of HCY,NGF, NTF, and IL-18 in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group（97.50%） was significantly higher than that in the control group（77.50%, P＜0.05）. After treatment, the FMA scores and BI scores in two groups were significantly higher than those before treatment（P＜0.05）, and the scores in the treatment group were significantly higher than those in the control group（P＜0.05）. After treatment, the levels of HCY and IL-18 in two groups were significantly lower than those before treatment, while the levels of NGF and NTF were significantly higher（P＜0.05）. After treatment,the levels of HCY, IL-18, NGF, and NTF in the treatment group were significantly better than those in the control group（P＜0.05）.Conclusion The combination therapy of nicergoline and betahistine can effectively alleviate patients’ symptoms, improve their daily living ability.

R971